L-Dopa Pharmacokinetic Profile with Effervescent Melevodopa/Carbidopa versus Standard-Release Levodopa/Carbidopa Tablets in Parkinson's Disease: A Randomised Study.

Parkinsons Dis · 2015 · PMC4478358 · PMID 26171276

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although the between-group difference did not reach statistical significance, absorption of V1512 absorption tended to be more rapid than that of L-dopa/carbidopa.

also in 111,027 other papers

a clear trendno p-value reported

We have previously demonstrated a clear trend towards improved overall control of the motor complications of Parkinson's disease with V1512 compared to L-dopa/carbidopa [ 27 ], and it is probable that these clinical advantages result from the more reliable and reproducible absorption of L-dopa from V1512.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.